Global Tissue-Based Genomic Profiling Market Projected to Reach USD 2.5 Billion by 2035

The global Tissue-Based Genomic Profiling Market is poised for steady growth over the next decade. Valued at USD 1.4 billion in 2025, it is expected to reach USD 2.5 billion by 2035, growing at a compound annual growth rate (CAGR) of 6.3% during the forecast period. This growth is underpinned by rising adoption of precision medicine, expanding use of genomic profiling in oncology, and increasing demand for actionable insights from genetic data.

With the increasing prevalence of cancer and complex diseases worldwide, healthcare providers and research institutions are turning to tissue-based genomic profiling for deeper understanding of tumor heterogeneity. Advances in next-generation sequencing (NGS) and bioinformatics have empowered clinicians to develop more effective, personalized treatment pathways, further driving market expansion.

Full Market Report available for delivery. For purchase or customization, please request here: https://www.futuremarketinsights.com/reports/sample/rep-gb-17583

Tumor Tissue and Liquid DNA Profiling Lead Technology Adoption

Among technology categories, tumor tissue and liquid DNA profiling is projected to capture 47.6% of the market by 2025, making it the dominant segment. This technology enables comprehensive genomic analysis from solid tumors as well as circulating DNA in bodily fluids, offering a dual advantage in early detection, therapy monitoring, and resistance profiling.

The integration of these assays into clinical workflows has enhanced their adoption in hospitals, diagnostic centers, and research institutes. Minimally invasive, highly informative, and compatible with targeted therapies, tumor tissue and liquid DNA profiling remains at the forefront of innovation in genomic diagnostics.

Personalized Medicine Emerges as Leading Application

The personalized medicine application segment is expected to account for 53.2% of market revenue by 2025. Rising emphasis on patient-centric care and precision therapies has made genomic profiling indispensable for customizing treatment pathways based on individual genetic variations.

Healthcare providers are leveraging tissue-based profiling to optimize drug selection, reduce adverse effects, and improve overall therapeutic outcomes. Pharmaceutical companies increasingly rely on biomarker-driven drug development, reinforcing the role of genomic profiling in clinical trials and patient management. The focus on personalized medicine continues to drive adoption across healthcare and research settings.

Research Institutes as Key End Users

Research institutes are projected to represent 41.8% of the tissue-based genomic profiling market by 2025. These institutes are at the forefront of cancer genomics research, biomarker discovery, and validation of companion diagnostics. Government-funded initiatives, biotechnology collaborations, and increasing investment in molecular diagnostics have strengthened the role of research institutions as leading end users.

By facilitating innovation, validating clinical applications, and expanding scientific knowledge, research institutes play a pivotal role in advancing the tissue-based genomic profiling market. Their work helps inform clinical practice and accelerates the translation of genomic discoveries into effective therapies.

Regional Market Insights

The United States leads the global tissue-based genomic profiling market, with an expected value of USD 2.5 million by 2035 at a CAGR of 5.7%. Strong government support, advanced genomic infrastructure, and initiatives like the NIH Precision Medicine Initiative and FDA regulatory frameworks for genetic testing have fostered market growth.

In the United Kingdom, market value is projected at USD 68.9 million by 2035, with a CAGR of 5.8%. Programs such as Genomics England’s 100,000 Genomes Project are integrating genomics into routine healthcare, driving adoption of tissue-based profiling for personalized treatments.

China is witnessing significant growth with a forecasted CAGR of 6.4% and an expected market size of USD 2.5 million by 2035. Increasing government support, investment in genomics research centers, and initiatives like the Healthy China 2035 plan are accelerating the adoption of tissue-based profiling in healthcare and drug discovery.

In Japan, market size is expected to reach USD 144.3 million by 2035 at a CAGR of 6.2%. The country’s advances in low-cost sequencing and genetic testing services have made tissue-based genomic profiling increasingly accessible to research institutions. South Korea is projected to reach USD 73.2 million by 2035 with a CAGR of 6.0%, supported by a well-established genomics infrastructure and collaborative efforts between government, academia, and industry.

Dominance of Tumor Profiling and Oncological Diagnostics

The tumor tissue and liquid DNA profiling segment is anticipated to continue leading the market with a CAGR of 7.7% through 2035. Tissue profiling identifies genetic mutations in cancer cells, guiding precise therapy selection, while liquid DNA profiling allows early detection and real-time monitoring. These complementary methods are increasingly integrated into oncological diagnostics, enhancing early intervention, treatment effectiveness, and patient outcomes.

Oncological diagnostics overall are expected to dominate tissue-based genomic profiling, driven by demand for non-invasive, early cancer detection. Diagnostic laboratories, which rely on genomic profiling for accurate, personalized diagnostic recommendations, are key contributors to market growth, with a projected CAGR of 7.1% from 2025 to 2035.

Request Market Research Draft Report: https://www.futuremarketinsights.com/reports/brochure/rep-gb-17583

Strategies of Leading Companies

The tissue-based genomic profiling industry is highly competitive, with key players employing various strategies to maintain market leadership. Product innovation remains central, with investments focused on improving sequencing efficiency, data analysis, accuracy, and sensitivity. Leading companies differentiate themselves by providing cutting-edge, reliable solutions.

Strategic partnerships and collaborations with research institutions, academic centers, and pharmaceutical companies enable knowledge sharing, access to novel biomarkers, and joint development of advanced diagnostic tools. Expanding into emerging markets allows companies to tap into growing demand for genomic profiling, while mergers and acquisitions consolidate market positions and broaden product portfolios.

Key Industry Players

Notable companies driving the tissue-based genomic profiling market include Foundation Medicine, Inc., Laboratory Corporation of America Holdings (PGDx), Illumina, Inc., QIAGEN, Roche Diagnostics, Thermo Fisher Scientific, and Exact Science. These players continue to innovate, form strategic collaborations, and expand their global presence, strengthening their competitive advantage.

Recent developments underscore this innovation. In September 2025, Foundation Medicine, Inc. presented 14 studies at the European Society for Medical Oncology Congress, highlighting the transformative power of genomic profiling in cancer care. In December 2025, the U.S. FDA approved FoundationOne Liquid CDx as a companion diagnostic for non-small cell lung cancer, further cementing the company’s role in advancing precision oncology.

Related Reports:

Canine Flu Therapeutics Market: https://www.futuremarketinsights.com/reports/canine-flu-therapeutics-market

Motorized Prosthesis Market: https://www.futuremarketinsights.com/reports/motorized-prosthesis-market

Sports Drug Testing Market: https://www.futuremarketinsights.com/reports/sports-drug-testing-market  

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:     

Future Market Insights Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com

Website: https://www.futuremarketinsights.com

LinkedIn| Twitter| Blogs | YouTube